A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy.
Federica Cavallo,Sara Bringhen,Giuseppe Milone,Dina Ben-Yehuda,Arnon Nagler,Elisabetta Calabrese,Nicola Cascavilla,Vittorio Montefusco,Barbara Lupo,Anna Marina Liberati,Claudia Crippa,Fausto Rossini,Roberto Passera,Francesca Patriarca,A. M. Cafro,Paola Omedè,A. M. Carella,Jacopo Peccatori,Lucio Catalano,Tommaso Caravita,Pellegrino Musto,M.T. Petrucci,Mario Boccadoro,Antonio Palumbo +23 more
TL;DR: It is confirmed that a short induction with lenalidomide allowed sufficient stem cells collection to perform autologous transplantation in 91% of newly diagnosed patients.
Journal ArticleDOI
Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.
Dror Mevorach,Tsila Zuckerman,Inna Reiner,Avichai Shimoni,Simcha Samuel,Arnon Nagler,Jacob M. Rowe,Reuven Or +7 more
TL;DR: It is suggested that a single infusion of donor ApoCell in HLA-matched allogeneic HSCT is a safe and potentially effective prophylaxis for acute GVHD occurring after myeloablative conditioning.
Journal ArticleDOI
Machine learning and artificial intelligence in haematology
TL;DR: The purpose of this review is to provide readers with tools to interpret and critically appraise machine learning literature and to discuss limitations of the machine‐learning approach.
Journal ArticleDOI
Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
Federico Lussana,Alessandro Rambaldi,Maria Chiara Finazzi,Anja van Biezen,Marijke Scholten,Elena Oldani,Alessandra Carobbio,Simona Iacobelli,Jürgen Finke,Arnon Nagler,Liisa Volin,Thierry Lamy,Renate Arnold,Mohamad Mohty,Mauricette Michallet,Theo de Witte,Eduardo Olavarria,Nicolaus Kröger +17 more
TL;DR: In this paper, a large retrospective study confirmed that transplantation is potentially curative for patients with end-stage polycythemia vera/essential thrombocythemia progressing to myelofibrosis or acute myeloid leukemia.
Journal ArticleDOI
Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: Similar outcomes with umbilical cord blood and unrelated donor peripheral blood
Celso Arrais Rodrigues,Vanderson Rocha,Peter Dreger,Claudio G. Brunstein,Henrik Sengeloev,Juergen Finke,Mohamad Mohty,Bernard Rio,Eefke Petersen,François Guilhot,Dietger Niederwieser,Jan J. Cornelissen,Pavel Jindra,Arnon Nagler,Nathalie Fegueux,Hélène Schoemans,Stephen D. Robinson,Annalisa Ruggeri,Eliane Gluckman,Carmen Canals,Anna Sureda,Anna Sureda +21 more
TL;DR: Umbilical cord blood is a valuable alternative for patients with lymphoid malignancies lacking an HLA-matched donor, being associated with lower risk of chronic graft-versus-host disease and higher risk of neutrophil engraftment after matched unrelated donor transplant.